Just don't sell, good potential to go to 50

Parkson looks like it's gonna break out today or tomorrow

Volume is coming back again

PP price set at only 26.5 sen. Just announced. So these buggers are going to sell for profit

Operator distributing now

It's a recovery stock

It's uptrend

If only Parkson can turn the corner due to the China consumer boom post covid & cost cutting in all its non performing stores in its rationalisation plan, it can easily turn in 100 million profit and that would translate into about 10 sen EPS. At forward PE of potential earnings 10x, this would propel the stock to RM1. 00. Not an impossible feat, cos we're already seeing the significant reduction in losses in the last quarter. Just hold tight.

Chart is very bullish

PP price not set yet

Khan, please go to respective threads to promote your stocks

Naivety kills

China recovery play

https://kennethvunyunlun.wordpress.com/category/criminal-trail/

The Fintech syndicate people behind it

Hi all, don't sell these precious deep value investing shares. It's rationalisation plans are bearing fruition now, will go back to its blue chip glorious days.

This is why, read all about these conmen

https://kennethvunyunlun.wordpress.com/category/criminal-trail/

PP tranches @ RM0.86 in Nov 2020, & Jan 3 & 18 all completed. These private placees have lost 50% of their shares value. I would believe Focus will push the share price up to the PP share price levels again to compensate them. My 2 cents worth.

Those who had bought at 10.5 would want to take a 40% profit now. Let them get out first.

Hold 1 — 2 months, will earn 100% from this level

Once break 12, will test Ema50 at 16.5 sen

It must break 12, then will go all the way

Kanger & Kstar gonna deal in Sinopharm vaccines once all regulatory approvals are in place

Report by The New York Times on Feb 5, 2021.
In the safety ranking, the top four are all Chinese vaccines:
1. Sinopharm (China)
2. Sinopharm (China)
3. Kexing (China)
4. Can Sino (China)
5. AstraZeneca (UK)
6. Pfizer (United States and Germany)
7. Modena (United States)
8. Johnson & Johnson (United States)
9. Novavax (United States)
10. Satellite 5 (Russia)
Sinopharm has two vaccines, ranking first and second respectively.
China has exported more than 500 million doses of vaccines to more than 50 countries around the world, and it is estimated that hundreds of millions of people have been vaccinated. And China's vaccine accident rate is lower and safer.
As reported by Western media, many wealthy people in Britain fly to the UAE to vaccinate Chinese national medicine.
《纽约时报》 2021年2月5日的报道。
在安全性排名中，排名前四的都是中国疫苗：
1.国药（中国）
2.国药（中国）
3.克星（中国）
4.信诺（中国）
5.阿斯利康（英国）
6.辉瑞（美国和德国）
7.摩德纳（美国）
8.强生（美国）
9. Novavax（美国）
10.卫星5（俄罗斯）
国药有两种疫苗，分别排名第一和第二。
中国已经向全球50多个国家出口了超过5亿剂疫苗，据估计已有数亿人接种了疫苗。 而且中国的疫苗事故率更低，更安全。
据西方媒体报道，英国许多有钱人飞往阿联酋为中药注射疫苗。

Khairy Welcomes Private Sector Procuring Approved Covid-19 Vaccines

codeblue.galencentre.org

Khairy Jamaluddin, head of the Covid-19 Immunisation Task Force (CITF), speaks at a press conference on February 17, 2021. Picture from Twitter @RembauForever.

KUALA LUMPUR, March 10 — Vaccine Minister Khairy Jamaluddin today encouraged the private sector to procure Covid-19 vaccines approved by local pharmaceutical regulators, paving the way for a potential parallel vaccine rollout by private health care providers.

Khairy was responding to a statement on Facebook by former Prime Minister Najib Razak, who asked the government to state clearly if private clinics and hospitals are able to purchase their own supply of Covid-19 vaccines, as currently there is mixed information on the involvement of private health care providers in the inoculation drive.

Najib pointed out that on March 6, Science, Technology, and Innovation Deputy Minister Ahmad Amzad Hashim said that although there were requests from the private sector to purchase Covid-19 vaccines through the government, the priority for the government is still to get adequate supply of vaccines for 80 per cent of the population. 

“With regards to the purchase of vaccines by the private sector, as I have mentioned yesterday, most of the vaccine manufacturers only carry out negotiations with governments,” Khairy responded to Najib in a comment on his Facebook post.

“If Dato’ Sri still doesn’t want to believe, I cannot do anything, I leave it up to Dato’ Sri.

“But if there are private parties who are able to carry out negotiations with vaccine manufacturers, especially those that have received approval from the NPRA (National Pharmaceutical Regulatory Agency) (Pfizer, AstraZeneca, and Sinovac), please do so. I really welcome it,” added the science, technology and innovation minister. 

Previously, Malaysian-based pharmaceutical company Pharmaniaga Bhd announced that it planned to sell some of its Sinovac vaccine doses to the private sector. Pharmaniaga is undertaking the fill-and-finish processing of Sinovac’s vaccine.

Solution Biologics, the distributor of Chinese CanSino’s vaccine, has also expressed plans to supply private health care providers with the vaccine, on top of selling 3.5 million doses to the Malaysian government. 

Private hospitals have previously urged the government to allow a parallel private Covid-19 vaccine rollout, with doses independently procured by private facilities, in order to expedite Malaysia’s vaccination coverage. As such, private health care providers have urged NPRA to quickly approve other Covid-19 vaccines authorised in other countries, such as Moderna. 

Khairy highlighted today that Malaysia targets to achieve herd immunity by February 2022, as mentioned in the National Covid-19 Immunisation Programme (PICK) guideline. 

He said that during the second and third phase of PICK, since the target number of daily doses administered will have to be raised up to 160,000, the Ministry of Health will increase the number of vaccinators to 7,000.

“With 7,000, we are able to achieve a number of more than 160,000. But we don’t want to over-promise as we are aware that vaccine supply will be sent over in stages,” Khairy told Najib. 

As Najib has raised multiple issues on the Covid-19 vaccine rollout several times on his Facebook page, Khairy invited Najib to a briefing on PICK, along with all other

The golden Cross will happen in the next few days & price will up to another level.

If you guys had read the circular, it did mention that they are finalising two construction projects worth RM163 million by 15 March. Just wait for them to pump up the price. Especially after the Special issue is completed.

I really missed brother Calvin, he's the only one who would impart his knowledge to others.

Special issue price as set out in the circular is 22.3 sen. You go figure it out

DLLM, do you see Kstar going back to the 20 sen level?

I was looking at Homily chart. The last support of 20.5 before the selldown had become the resistance now.

Next resistance 16.5 sen

DK, may I suggest that you create a group chat on telegram. All JAKS supporters can then follow using mobile phones cos everybody moves around.

The special issue for Bumis was indicated at 10.5sen, so I believe, this is the support price now. It has already bottomed out. Now be patient and wait for its listing under SAG.

Hi DK, please add me to your group chat. TQ

DLL, what does the dragonfly Doji signify?

Wait a while more to flush out contra players who are caught at high levels.

So they have now have to suppress the price very low to buy back in order to replace the shares they had used to trade for a gain. And due to very high volume during the pump earlier, retailers caught at the high on contra have to sell lower & lower cos today is T3 for the big volume earlier.

This selldown is all because of one party who had pledged his shares to UBS and the bank exercised their right to rehypothecate the shares and sold down all the way. This had all been done with.

Please refer to announcements

This selldown is all because of one party who had pledged his shares to UBS and the bank exercised their right to rehypothecate the shares and sold down all the way. This had all been done with.

Why James keep mentioning the shoes business, it's going to assume a new corporate identity very soon under Sinaran Advance

This James Ng not relevant laaa

Can expect some activity soon, please go read up on the company's announcements today

I should think kstar is building a slope now

11 sen CASH PER SHARE

Kstar is going to assume a new entity soon under Sinaran. Uptrend.

With RM150mm in the accounts, can be tempting to corporate vultures

The circular says that the proceeds are for gloves business at its premises. If this is not the case, this has become a corporate cheat of the PPs.